Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), anticipates a significant increase in profits for the fiscal year ending December 31, 2025, projecting earnings between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to an estimated profit of about $2.7 million for the fiscal year ending December 31, 2024 [1]. Financial Projections - The adjusted total profit is expected to range from $91 million (approximately HKD 708 million) to $98 million (approximately HKD 763 million) [1]. - The profit increase is primarily attributed to the continuous growth of the company's recurring revenue [1]. Revenue Drivers - Revenue growth is supported by research collaborations with AstraZeneca and Bristol-Myers Squibb [1]. - The accelerated expansion of the global partnership network has also contributed to revenue growth, including licensing collaborations with Otsuka Pharmaceutical and Windward Bio [1]. - Rapid growth in the business of Nona Bio, including revenue from technology licensing and platform-based services, as well as milestone payments from research and technology licensing collaborations with Pfizer, has further enhanced revenue [1].
和铂医药-B预计2025年溢利达8800万美元至9500万美元